MBX Biosciences, Inc. Common Stock

MBX Biosciences announced that its Board of Directors has appointed Steve Hoerter, currently Executive Chairman, as Chairman and Chief Executive Officer, succeeding Kent Hawryluk who steps down as President, CEO and board member. The Board also named John Smither, who has served as Interim CFO since March 2026, as the company's new Chief Financial Officer, with all changes effective immediately. Hoerter, who joined the board in April 2025 and became Executive Chairman in November 2025, previously led Deciphera Pharmaceuticals as President and CEO through its acquisition by Ono Pharmaceutical. Smither brings over 25 years of biopharmaceutical financial leadership, most recently as CFO of Arcutis Biotherapeutics. The company reaffirmed its three key milestones for the second half of 2026: initiating a Phase 3 trial of canvuparatide in chronic hypoparathyroidism, nominating a GLP-1/GIP/GCGR triple agonist candidate for obesity, and reporting 12-week multiple ascending dose data from MBX 4291.

Six biotech stocks profiled by RTTNews have delivered stunning gains for patient investors, with Inhibrx Biosciences surging as much as 746% since its profile was published on July 8, 2025. Palvella Therapeutics rose up to 505% from its March 10, 2025 profile, driven by positive trial results and an FDA rolling review for its rare-disease therapy. MBX Biosciences gained up to 363% since June 18, 2025, following encouraging data from multiple clinical programs. Protagonist Therapeutics advanced as much as 204% from its January 6, 2025 profile after FDA approval of its psoriasis drug. Absci Corp. climbed up to 290% since September 12, 2025, on positive interim data for its AI-designed hair-loss treatment. Belite Bio increased up to 187% from its September 15, 2025 profile, supported by a completed rolling NDA submission for its retinal-disease therapy.